Long-acting pegylated human GH in children with GH deficiency: A single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics

European Journal of Endocrinology

Volumn 165, Issue 3, 2011, Pages 401-409

  De Schepper, Jean ^a,b   Rasmussen, Michael Højby ^c   Gucev, Zoran ^d   Eliakim, Alon ^e   Battelino, Tadej ^f  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c NOVO NORDISK A S   (Denmark)

^d Clinic of Children Diseases   (Macedonia)

^e MEIR MEDICAL CENTER   (Israel)

^f UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; LONG ACTING DRUG; LONG ACTING PEGYLATED HUMAN GROWTH HORMONE; NNC 126 0083; SOMATOMEDIN C; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MACROGOL DERIVATIVE; NNC126 0083; NNC126-0083;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; PANCYTOPENIA; PHARMACODYNAMICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG TOXICITY; METABOLISM; RANDOMIZED CONTROLLED TRIAL; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPOATROPHY; MAJOR CLINICAL STUDY; PATIENT SATISFACTION; SIDE EFFECT; VIRUS INFECTION;

AREA UNDER CURVE; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; POLYETHYLENE GLYCOLS;

EID: 80051699844     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0536     Document Type: Article

References (27)

1. Desrosiers P, O'Brien F & Blethen S. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatric Endocrinology Reviews 2005 2 (Supplement 3) 327-331. (Pubitemid 40469491)
2. Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, Ong KK & Acerini CL. Monitoring of concordance in growth hormone therapy. Archives of Disease in Childhood 2008 93 147-148. (doi:10.1136/adc.2006.114249)
3. Rosenfeld RG & Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocrine Practice 2008 14 143-154.
4. Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, Jorgensen JO & Christiansen JS. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 2001 86 1222-1228. (doi:10.1210/jc.86.3.1222)
5. Tauber M, De Bouet Du PH, Sallerin-Caute B, Rochiccioli P & Bastide R. Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children. Journal of Clinical Endocrinology and Metabolism 1993 76 1135-1139. (doi:10.1210/jc.76.5.1135)
6. Rasmussen MH, Jensen L, Anderson TW, Klitgaard T & Madsen J. Multiple doses of pegylated long-acting growth hormone is well tolerated in healthy male volunteers and possesses a potential once-weekly treatment profile. Clinical Endocrinology 2010 73 769-776. (doi:10.1111/j.1365-2265.2010.03863.x)
7. Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T & Madsen J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. Journal of Clinical Endocrinology and Metabolism 2010 95 3411-3417. (doi:10.1210/jc.2009-2813)
8. Søndergaard E, Klose M, Hansen M, Hansen BS, Andersen M, Feldt-Rasmussen U, Laursen T, Rasmussen MH & Christiansen JS. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile and multiple-dosing is well-tolerated in adult patients with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 2010 96 681-688. (doi:10.1210/jc.2010-1931)
9. 1996 International Conference on Harmonisation, harmonised tripartite guideline: guideline for good clinical practice E6(R1), 1996. ICH secretariat, Geneva, Switzerland.
10. World medical association declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964; latest amendment made by the 59th WMA General Assembly, Seoul, October 2008.
11. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Muller J & Skakkebaek NE. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. Journal of Clinical Endocrinology and Metabolism 1995 80 2534-2542. (doi:10.1210/jc.80.8.2534)
12. Veronese FM & Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today 2005 10 1451-1458. (doi:10.1016/S1359-6446(05) 03575-0)
13. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L & Smith D. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metabolism and Disposition 2007 35 9-16. (doi:10.1124/dmd.106.012419)
14. Hamidi M, Rafiei P & Azadi M. Designing PEGylated therapeutic molecules: advantages in ADMET properties. Expert Opinion on Drug Discovery 2008 11 1293-1307. (doi:10.1517/17460441.3.11.1293)
15. Laursen T, Jorgensen JO, Jakobsen G, Hansen BL & Christiansen JS. Continuous infusionversus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 1995 80 2410-2418. (doi:10.1210/jc.80.8.2410)
16. Iranmanesh A, Grisso B & Veldhuis JD. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. Journal of Clinical Endocrinology and Metabolism 1994 78 526-535. (doi:10.1210/jc.78.3.526)
17. Reiter EO, Price DA, Wilton P, Albertsson-Wikland K & Ranke MB. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. Journal of Clinical Endocrinology and Metabolism 2006 91 2047-2054. (doi:10.1210/jc.2005-2284)
18. Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek NE & Christiansen JS. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989 1 1221-1225. (doi:10.1016/S0140- 6736(89)92328-3)
19. van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van Doorn J, Dekkers OM, Roelfsema F & Pereira AM. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. European Journal of Endocrinology 2006 155 701-708. (doi:10.1530/eje.1.02283)
20. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G & Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. Journal of Bone and Mineral Research 2002 17 1081-1094. (doi:10.1359/jbmr.2002.17.6.1081)
21. Laursen T. Clinical pharmacological aspects of growth hormone administration. Growth Hormone & IGF Research 2004 14 16-44. (doi:10.1016/j.ghir.2003.10.001)
22. Johansson JO, Oscarsson J, Bjarnason R & Bengtsson BA. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis. Metabolism 1996 45 362-369. (doi:10.1016/S0026-0495(96)90292-9)
23. Oscarsson J, Ottosson M, Johansson JO, Wiklund O, Marin P, Bjorntorp P & Bengtsson BA. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. Metabolism 1996 45 370-377. (doi:10.1016/S0026-0495(96)90293-0)
24. Laursen T, Lemming L, Jorgensen JO, Klausen IC & Christiansen JS. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients. Hormone Research 1998 50 284-291. (doi:10.1159/000023292)
25. Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SF, Neuwirth RB, Ford KM & Saenger P. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 4700-4706. (doi:10.1210/jc.86.10.4700)
26. Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB & Ford KM. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. Journal of Pediatric Endocrinology and Metabolism 2002 15 (Supplement 2) 715-722. (doi:10.1515/JPEM.2002.15.S2.715)
27. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T & Lippe B. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. Journal of Clinical Endocrinology and Metabolism 2005 90 6431-6440. (doi:10.1210/jc.2005-0928)